Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating the Safety of GAMMAGARD LIQUID for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT05363358 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05363358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05363358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating the Safety of GAMMAGARD LIQUID for the Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Lead sponsor
Takeda
Phase
Observational
Overall status
Completed
Start date
May 27, 2022
Completion date
December 1, 2022
Enrollment
6,086 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic inflammatory demyelinating polyradiculoneuropathy (cidp)